Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary
November 3, 2022
Earnings Call Speaker Segments
Zack Kubow
executiveThanks a lot, operator, and good afternoon to all of you. We appreciate you being here for the Corvus Pharmaceuticals conference call covering our third quarter 2022 business update and financial results. Joining us to talk through the results and business updates are Richard Miller, our Chief Executive Officer; Leiv Lea, our Chief Financial Officer; and James Rosenbaum, our Senior Vice President of Research. The executive team will kick things off with a few prepared remarks, and after that we'll move into a question-and-answer period. I want to remind all of you that today's comments from management, along with responses to questions, will contain forward-looking statements. Such statements rest on estimates and assumptions as of today and carry risks and uncertainties that could lead to actual results differing materially from what those statements express or imply, including the risks and uncertainties laid out in Corvus' quarterly report on Form 10-Q, filed with the SEC today, as well as other filings the company makes with the SEC from time to time. The company has no obligation to publicly update or revise any forward-looking statements except as the law requires. With that said, I'd like to hand the call over to Leiv Lea. Leiv?
Leiv Lea
executiveThanks, Zack. I'll start by giving a brief look at how our finances came in for the third quarter of 2022, and after that I'll hand things to Richard for an update on the business. As of September 30, 2022, Corvus held cash, cash equivalents and marketable securities adding up to $49.6 million, which compares with $69.5 million on December 31, 2021. Given how we recently reordered priorities across our clinical stage pipeline plans, we expect that our cash will fund us into early 2024. R&D expenses for the third quarter of 2022 came to $10.4 million, versus $7 million during the same period in 2021. That $3.4 million increase was mostly driven by a $5.5 million rise in drug manufacturing costs, partly offset by a $2.2 million decrease in clinical trial costs. As you can tell, we keep managing our cash burn rate prudently while moving our portfolio of product candidates forward. We pulled this off through careful use of seasoned personnel, drawing on outside resources, and setting up collaborations that assist in supporting development of our products. Among those collaborations are Angel Pharmaceuticals, our partner in China that is now taking part in clinical trials with CPI-818 and mupadolimab, and the Kidney Cancer Consortium, which is running a first-line trial with ciforadenant in combination with ipilimumab and nivolumab for renal cell cancer. Net loss for the third quarter of 2022 was $14.8 million, versus a net loss of $10.7 million during the same period in 2021. Total stock compensation expense for the third quarter of 2022 was $0.7 million, compared with $1.1 million during the same period in 2021. I'll now hand the call to Richard, who will go into more detail on our strategy and plans.
Richard Miller
executiveThanks, Leiv, and hello everybody this afternoon. We appreciate your presence with us for today's update on business results from the third quarter of 2022. It's a pleasure to provide news about our clinical efforts, which are designed to deliver novel treatment methods for numerous conditions, among them cancer along with immune-mediated illnesses. Our plan is to achieve this through adjusting how immune cells function, using drugs we have designed to hit precise targets. With the year drawing to a close, we find ourselves ready for multiple possible catalysts throughout our pipeline, with the aim of broadening our capacity to assist additional patients. At the forefront of our efforts stands CPI-818, an ITK inhibitor that we think holds varied potential spanning oncology, autoimmunity, fibrotic conditions and allergic disorders. CPI-818 works as a covalent ITK inhibitor, attaching to ITK in a manner comparable to how ibrutinib attaches to BTK; we think the chance with CPI-818 to go after T cells mirrors what BTK inhibitors and anti-CD20 antibodies achieve by going after B cells for treating both B cell lymphomas and autoimmune conditions. Crucially, people on the Corvus team were instrumental in finding and creating these agents; to our knowledge, no other ITK inhibitors are presently undergoing clinical testing. Right now CPI-818 is under investigation in a Phase 1/1b clinical trial involving individuals with relapsed T cell lymphoma. We have settled on 200 milligrams taken orally twice daily as the optimal dose, and Corvus, together with Angel Pharmaceuticals, our partner in China, is growing a patient group centered on that dose. This morning we shared that findings from this trial are set to be shown in a poster session at the American Society of Hematology Meeting taking place on December 12. As we reported earlier, by July 22 there were eight evaluable patients who had received the 200 milligram BID dose; among them we saw one complete response, one nodal complete response, one partial response and five whose disease remained stable; we consider these outcomes favorable considering how severe the illness is. For these patients, the median number of prior therapies was four, and first relapsed T cell lymphoma has a published overall survival median of 5.6 months, while progression-free survival in first relapse is under three months; in contrast, our patients had experienced three or four relapses. The ASH update will feature more mature data on safety and antitumor activity among patients in this 200 milligram cohort. Furthermore, the presentation will cover analyses of how CPI-818 modulates immunity in normal T cells, assessed through shifts in Th1, Th2, Th17 cells and what are termed terminally differentiated T effector memory cells, as well as different serum cytokines found in blood samples taken from these patients. Such immunomodulatory impacts carry significant consequences for treating autoimmune and allergic conditions. Moving forward with our approach for CPI-818 in autoimmunity and allergy represents a key priority for the company, under the leadership of Dr. James Rosenbaum, who came aboard in July. From what we've been doing, our confidence keeps growing that during the first half of 2023 we'll kick off clinical trials in autoimmune and/or allergic diseases. In addition, we intend to start a Phase 2 study of CPI-818 in T cell lymphoma during 2023. Should time permit, Dr. Rosenbaum will go into further detail on this in our Q&A; on December 12, while at the ASH meeting, we're planning a conference call and webcast so we can talk over the CPI-818 data plus updates regarding our plans for CPI-818 in autoimmune disease and allergy. Our ASH curtain raiser and third quarter results press releases today contain initial details about that call, and closer to when the event takes place, more specifics will be shared. Now turning to ciforadenant, our adenosine 2a receptor antagonist. Back in October, the Kidney Cancer Research Consortium began a Phase Ib/II clinical trial looking at ciforadenant as a possible first-line therapy for metastatic renal cell cancer, used in a triplet combination alongside ipilimumab and nivolumab. The University of Texas MD Anderson Cancer Center was leading that trial, and it's among the seven partner institutions forming the consortium. Every member is a premier institution, and the others are Beth Israel Deaconess, Duke University, University of Michigan, University of Pennsylvania, UT Southwestern and Vanderbilt. That trial draws on our 2018 publication, which showed synergy between ciforadenant and anti-CTLA-4 antibody in preclinical tumor models, as well as data from our Phase I studies demonstrating cifo's antitumor activity. Up to 60 patients are planned for enrollment, all with newly diagnosed or recurrent Stage IV renal cell cancer who haven't had any prior systemic therapy. The regimen for patients is cifo 100 milligrams taken orally twice daily on a continuous basis, combined with ipi 1 milligram per kilogram once every three weeks for four doses, and nivolumab 3 milligram — 3 mgs/kg administered every three weeks. For this disease, those regimens are fairly standard. Eight patients will be enrolled in the Phase Ib run-in portion, with primary end points of safety, tolerability and antitumor activity. Over in the Phase II portion, the primary endpoint is the percent of patients achieving deep responses. That's defined as CRs, complete responses, and partial responses featuring greater than 50% reduction in tumor volume, which reflects our goal of raising the plateau on the progression-free survival and overall survival by adding cifo. Historical data from those institutions I just mentioned has shown deep responses correlate with prolonged progression-free survival and is seen in approximately 32% of patients receiving ipi/nivo. As a reminder, this trial is open-label and single-arm, so we anticipate getting a good feel for efficacy early in the trial. Next is mupadolimab, our B cell activating anti-CD73 antibody; we believe mupadolimab is differentiated in the CD73 landscape as it binds to a unique epitope on the CD73 protein, which on B cells results in their activation and differentiation into antibody-producing plasma cells and into memory B cells. Our view is that the immune-modulating effects give us a distinctive way of acting within immunotherapy. We expect that soon our collaborator Angel Pharmaceuticals will launch a Phase I/Ib study in China testing mupadolimab as a single agent and in combination with pembrolizumab among individuals suffering from relapsed/refractory non-small cell lung cancer as well as those with head and neck squamous cell cancers. Within the US, we are still on hold yet prepared to move mupadolimab forward into a randomized controlled Phase II trial while we keep directing our resources toward developing 818; to wrap up, we feel Corvus sits in a strong spot with multiple possible catalysts across our programs over the next 12 months alongside a cash runway reaching into early 2024. Among the important near-term milestones, fresh CPI-818 Phase I results will be shared at ASH in December. As a reminder, this study involves Angel Pharmaceuticals, which handles that China-based portion, and we intend to run a Phase II trial for T-cell lymphoma during 2023. Work on CPI-818 for autoimmune and allergy indications is continuing, aiming to start clinical trials within the first half of 2023. Regarding ciforadenant, our Phase Ib/II trial in first-line renal cell cancer may allow us to see clinical activity response rate data early in enrollment because the study is open-label. Meanwhile, mupadolimab development keeps moving in China, with Angel Pharmaceuticals set to begin a Phase I trial that might produce new data next year. We are eager to share updates on these key initiatives over the coming quarters. At this point I will hand the call to the operator for the questions-and-answer period. Operator?
Jerry Gong
analystHello. Jerry Gong here, filling in for Mara Goldstein. I appreciate you answering our questions. Also, congratulations regarding the accepted abstract. About the CPI-818 study that's still running, could you verify whether any participants in the higher dose groups remain under monitoring? In addition, might you share some detail on how CPI-818 patients in that trial break down between China versus, say, the US or Australia? Thank you.
Richard Miller
executiveEnrollment has closed for the higher dose groups, meaning 400 milligrams and 600 milligrams. Our main emphasis at the ASH meeting will be the continuing accrual and follow-up of patients receiving 200 milligrams. One point worth stressing, given what you asked: we have found a quite notable dose response relationship with this drug. And 200 milligrams is a dose — likely 200 milligrams through 400 milligrams is a dose — that we believe carries very meaningful consequences for T cell differentiation. Nothing like this had been reported before. I should mention we believe we hold intriguing intellectual property covering this. And we will push that point strongly at the ASH meeting, covering not just the antitumor activity but likewise the impact on normal T cell biology. The second question was — Jerry, what did you ask second?
Jerry Gong
analystYeah, apologies; could you give us some detail regarding how CPI-818 patients in the study split between China, the US, or Australia?
Richard Miller
executiveThe bulk of patients dosed in our study have come from the US, with a number from Australia and South Korea. Lately, enrollment has been arriving in a big way from China, along with here.
Jerry Gong
analystUnderstood, and may I pose a second follow-up? China has lately restated its commitment to a zero-COVID approach. In what ways could that influence ongoing clinical studies there, among them CPI-818 and the Mupa trial, which only just received IND clearance?
Richard Miller
executiveWe have been watching this situation quite closely. My view is that the zero-COVID approach did not meaningfully disrupt our China trial; at present we have just 4 or 5 sites, and a number of them began operating only a short time ago. Over the past several weeks, it seems the zero-COVID approach, or the COVID pandemic in China, has eased. As things stand, we are observing no material effect on that.
Jerry Gong
analystUnderstood. I appreciate the additional detail.
Roger Song
analystExcellent. Thank you for fielding our questions, and congratulations on the advancement. Rich, perhaps a few things regarding 818. Given what I see in the press release and your prepared comments, you're putting autoimmune or allergic disease first for 818. Could you remind everyone what biological mechanism 818 is intended to target in those conditions? Also, would you verify what the upcoming move will be for 818, especially concerning the US and globally beyond China?
Richard Miller
executiveAlright. Let me begin by stressing that T-cell lymphoma remains our primary focus; we continue to regard T-cell lymphomas as the most efficient, most effective, shortest route to approval for a serious illness, and we believe our drug can benefit patients suffering from it. Our conviction stands that we can achieve a meaningful impact as a monotherapy in relapsed disease. Naturally, in the longer term, we'd aim to combine it for patients with lymphoma at earlier stages; so I want to underscore that T-cell lymphoma is still the central focus of what we're doing. That said, it's extremely hard to overlook the dramatic effects observed in our lymphoma patients, strongly recalling what my colleagues and I witnessed when we began treating lymphoma patients with agents such as Rituxan and ibrutinib, we started to observe that there were consequences for other B-cells in that instance, whereas with ITK, it's T-cells that might truly matter for numerous other conditions; so the effects we're seeing and will discuss at ASH, and there's plenty of genuinely exciting material on our poster at ASH. It concerns how 818 influences the differentiation of so-called T helper cells. There's no doubt this produces skewing or biasing toward Th1 T-cells. Th1 cells play a key role in destroying cancer cells and destroying virally infected cells. And without question we possess in vivo proof of this; we have in vitro proof of this, that we can bring about striking suppression of Th2 and its downstream cytokines such as IL-4, IL-5, IL-13. Such cytokines are pathologic in conditions including asthma, atopic dermatitis, scleroderma and numerous, numerous other conditions. So our approach is to push ahead aggressively with T-cell lymphoma as much as possible, while simultaneously directing our resources toward launching autoimmune disease trials in 2023. And I believe this could be a suitable moment to hand things over to Dr. Rosenbaum, who might offer somewhat more detail on what you're asking; so, what matters most for us, considering the vast number of opportunities in autoimmunity, is whether we can select an autoimmune or allergic disease where we can enter the clinic swiftly, obtain fairly short endpoints and secure meaningful clinical data in 2023; and that is precisely what we plan to do. We'll be sharing much more on that during our call about ASH. Jim, is there anything you'd like to add?
James Rosenbaum
executiveRichard, thank you. Absolutely, happy to. As you mentioned, 818 forms a covalent bond with ITK, which is an enzyme found in T-cells and plays an essential role in producing what are known as Th2 cells — the T-cell subset that matters greatly in allergic and atopic disease as well as fibrotic disease. At this point, we're inclined to pursue atopic dermatitis as the initial clinical indication, since the scientific case for Th2 cells contributing to that condition is extremely strong. Beyond that, it represents an unmet clinical need, with existing drugs that work only partially or sometimes work at all, and frequently these are medications that must be administered via injection. 818, naturally, is taken orally. Its mechanism of action is distinctive. And what's appealing is our belief that clinical efficacy could be identified within 28 days. So our plan is to enter clinical trials during the spring of 2023, and we anticipate obtaining results that will clarify efficacy prior to the close of 2023. And as you noted, additional information will be shared at the ASH conference taking place on December 12.
Richard Miller
executiveThanks, Jim. So, Roger, any follow-up questions on that?
Roger Song
analystYeah, I believe that's excellent. What I'm really anticipating is the information coming out of both the lymphoma area and autoimmune disease. So perhaps as a quick follow-up regarding grasping Mupa — you're putting 818 first, yet at the same time you're moving Mupa ahead in China. So maybe, at what point will there be news on Mupa's progress within the US or beyond China?
Richard Miller
executiveAll right. So we anticipate beginning to enroll patients in China prior to the close of this year. The IND has received approval in China. And Angel has already secured several excellent clinical sites, with well-known experts in lung cancer and head and neck cancer involved. Naturally, those trials are non-randomized. However, it will cover Mupa by itself as well as Mupa combined with pembro. Now regarding the US, as you're aware, our plans for a randomized Phase II trial have been paused. That was a frontline lung cancer study. I can't give any firm timeline for when we might launch — relaunch that here in the US. Once again, our strong emphasis right now is on 818. Clearly, circumstances might shift, since we possess a protocol, we have sites prepared, we have a collaboration, we're all set to proceed with our Mupa Phase II trial, everything is ready. The only reason we halted it was, first, to preserve some capital, and second, to genuinely seek results from other parties who are also active in this space. We have — we've constantly faced the burden of being the trailblazer; so here, we were the trailblazer, but at this point we're going to hold back and let some of these other efforts unfold. Now, Roger, as you're certainly aware, there are additional lung cancer studies involving TIGIT antibodies and other agents under investigation. Those findings will arrive shortly, within the coming several months. They might likewise affect what we plan to do.
Richard Miller
executiveRoger, understood. Richard here. Alright, since that subject has come up — it's a fair thing to raise. The identical question could apply to ciforadenant or ciforadenant; my colleagues keep teasing me about how I say it. Regardless, cifo, using cifo in the frontline alongside ipi/nivo makes for a genuinely intriguing study. The underlying science and the reasoning there are pretty compelling. Together with several of our partners, we've identified a truly novel mechanism of action. Once we present it to everyone, it will completely click. We aren't ready to reveal that just yet, since we need to shore up our intellectual property and so forth; however, it appears there is genuinely something remarkable there. I'm eagerly anticipating those results. Another aspect of that study: it relies on CR and on what we refer to as deep PRs. A few papers have already come out showing that deep PRs and CRs track with PFS and OS. Consequently, the majority of patients who do respond will do so within 3 months; that means we'd learn quite fast, quite early on in the trial, if we're moving this deep PR/CR rate, which, as I noted during my remarks, sits at roughly 32% in the published literature. Does that make sense?
Roger Song
analystFantastic. That's excellent, and I appreciate the extra detail regarding the cifo. Thanks a lot.
Analyst
analystHello there. Rosemary here, filling in for Li. I really appreciate you taking my question. There are just two quick things I'd like to ask. First, regarding CPI-818, how quickly do you believe you could advance into Phase 2? Also, have you spoken with the FDA about a possible route to approval? Then, about cifo ciforadenant — when combined with ipi and nivo in frontline renal cell, what in your opinion would count as good data?
Richard Miller
executiveAll right. The initial question concerns T-cell lymphoma. So, once again, our intention would be to treat patients with monotherapy, specifically refractory peripheral T-cell lymphomas along with cutaneous T-cell lymphomas. A protocol has already been written by us. It's being passed around to two investigators. That protocol hasn't been reviewed with the FDA yet. Our plan would be to launch that study around midyear. And once more, that would be a single-arm study. We can discuss more regarding that at the ASH meeting, in terms of our thinking on size; but you're likely looking at a study involving 100 patients, 150 patients, or something along those lines. As for the second question — what would constitute success — that's a wonderful question, since, as I noted during my remarks, a few papers have demonstrated that deep PR and CR comes to 32%. So, my aim is to exceed 32%. Quite straightforward.
Analyst
analystCould it go higher than 32%?
Richard Miller
executiveHonestly, 52% would be my preference, but...
Analyst
analystOf course, understood.
Richard Miller
executiveThat said, what I'm getting at is that 32% basically reflects what you've seen historically — at least in the recent past.
Richard Miller
executiveUnderstood, thanks a lot. Yeah, I’d just like to mention one more point: although everyone’s enthusiastic about immuno-oncology and immunotherapies, it deserves emphasis that — and undoubtedly, in many instances, PFS and OS along with response rates have gone up, particularly in cases such as renal cell cancer; yet what’s intriguing is that the complete remission rate, the complete remission rate, hasn’t truly risen all that much. And the majority of skilled oncologists are after CRs, since CRs may lead to cures, whereas PRs never lead to cures — almost never. So, what you’ll be focusing on is CR and deep PR rate response rate. All right. Apologies, operator, any other —
Richard Miller
executiveAll right, that's fine.
Richard Miller
executiveAll right, then. Thanks, operator. To start, I want to thank all of you for joining us on this call. We appreciate the interest. We're eager for our upcoming call on December 12, which will be from New Orleans. We hope to bring you an update at that time, along with the standard quarterly updates as we progress toward the close of the year and into 2023. Many thanks.
Operator
operatorThat brings today's call to a close. Thanks for joining us for the presentation. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.